NCT05397171View on ClinicalTrials.gov

A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

June 7, 2022

Primary Completion Date

June 6, 2023

Study Completion Date

June 6, 2023

Conditions
Urinary Bladder NeoplasmsColorectal CancerCarcinoma, Non-Small-Cell Lung
Interventions
DRUG

AZD8853

Monotherapy given until progressive disease or upon meeting other discontinuation criteria.

DRUG

Zirconium-89 crefmirlimab berdoxam

CD8+ T cell tracer for positron emission tomography (PET) at two time points in addition to monotherapy AZD8853

Trial Locations (6)

30322

Research Site, Atlanta

63110

Research Site, St Louis

98109

Research Site, Seattle

02903

Research Site, Providence

K1H 8L6

Research Site, Ottawa

M5G 1X5

Research Site, Toronto

Sponsors

Lead Sponsor

AstraZeneca

Collaborators (1)

ImaginAb, Inc.
All Listed Sponsors
collaborator

ImaginAb, Inc.

INDUSTRY

lead

AstraZeneca

INDUSTRY